Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 400mg;   - modified release tablet - 400 mg - active: carbamazepine 400mg   excipient: carmellose sodium colloidal silicon dioxide ethylcellulose hypromellose yellow, red, white suspension iron oxide red iron oxide yellow magnesium stearate methacrylic acid copolymer microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified talc   purified water titanium dioxide - epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - lapatinib ditosilate monohydrate 405mg equivalent to 250 mg lapatinib free base - tablet - 250 mg - active: lapatinib ditosilate monohydrate 405mg equivalent to 250 mg lapatinib free base excipient: magnesium stearate microcrystalline cellulose opadry yellow ys-1-12524-a povidone sodium starch glycolate - her2-positive (her2+) overexpressing metastatic breast cancer tykerb, in combination with capecitabine, is indicated for the treatment of patients with advanced/metastatic breast cancer whose tumours overexpress her2 (erbb2) and whose tumours have progressed after treatment with an anthracycline and a taxane, and who have progressed on prior trastuzumab therapy in the metastatic setting. tykerb, in combination with paclitaxel, is indicated for the first-line treatment of patients with metastatic breast cancer whose tumours overexpress her2 (erbb2) and for whom trastuzumab is not appropriate. hormone receptor-positive metastatic breast cancer tykerb, in combination with an aromatase inhibitor, is indicated for the treatment of post-menopausal women with hormone receptor-positive metastatic breast cancer whose tumours overexpress her2 (erbb2) and for whom hormonal therapy is indicated.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

biocelect new zealand ltd - salmonella typhi strain ty21a berna 2000 million organisms (minimum); salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum); salmonella typhi strain ty21a berna 2000 million organisms - modified release capsule - 2000 million organisms - active: salmonella typhi strain ty21a berna 2000 million organisms (minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate lactose fast flo iron oxide red iron oxide yellow lactose monohydrate magnesium stearate sucrose titanium dioxide active: salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate sucrose titanium dioxide active: salmonella typhi strain ty21a berna 2000 million organisms excipient: ascorbic acid diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate methanol methylene chloride protein hydrolysate sucrose titanium dioxide - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 25 mg/ml;   - solution for injection - 75mg/3ml - active: diclofenac sodium 25 mg/ml   excipient: benzyl alcohol mannitol propylene glycol sodium hydroxide sodium metabisulfite water for injection - treatment of biliary colic.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 100mg;   - suppository - 100 mg - active: diclofenac sodium 100mg   excipient: hard fat - · treatment of inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 12.5mg;   - suppository - 12.5 mg - active: diclofenac sodium 12.5mg   excipient: hard fat - · treatment of inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 25mg;   - suppository - 25 mg - active: diclofenac sodium 25mg   excipient: hard fat - · treatment of inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 50mg;   - suppository - 50 mg - active: diclofenac sodium 50mg   excipient: hard fat - · treatment of inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 1 mg/ml;  ;   - eye drops, solution - 1 mg/ml - active: diclofenac sodium 1 mg/ml     excipient: benzalkonium chloride disodium edetate dihydrate hydrochloric acid hydroxypropyl gamma-cyclodextrin propylene glycol trometamol tyloxapol water for injection

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 1 mg/ml;   - eye drops, solution - 300 mcg/0.3ml - active: diclofenac sodium 1 mg/ml   excipient: boric acid polyoxyl 35 castor oil trometamol water for injection - voltaren ophtha eye drops are indicated for: · post-operative inflammation in cataract surgery and other surgical interventions. · prevention of cystoid macular oedema after cataract extraction with lens implantation. · post-traumatic inflammation in non-penetrating wounds. · inhibition of miosis in cataract surgery. · relief of pain and photophobia. · non-infected inflammatory conditions of the anterior segment of the eye.